Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab Vedotin + Tislelizumab + Bevacizumab in HER2-Altered NSCLC
NCT06749860Phase 2Recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Feb 2024
- Primary completion
- Jun 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of disitamab vedotin in non-small cell lung cancer (NSCLC), sponsored by Shanghai Pulmonary Hospital. Started Feb 2024; status: recruiting.
02
Drugs
disitamab vedotin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06749860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06749860.